Teucrium Corn Fund vs Citius Pharmaceuticals Inc — how do they compare? Teucrium Corn Fund trades at $18.99 (market cap $122.67M), while Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M). The key difference: Teucrium Corn Fund is far larger — about 8.9× Citius Pharmaceuticals Inc's market cap, and Teucrium Corn Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Corn Fund for 26 Days and Citius Pharmaceuticals Inc for 16 Days on average.
| CORN | CTXR | |
|---|---|---|
Market Cap | $122.67M | $13.79M |
Volume | 103,450 | 156,684 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $20.29 | $1.82 |
52-Week Low | $16.46 | $0.48 |
Typical Hold Time | 26 Days | 16 Days |
Enterprise Value | — | $3.96M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →